

To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): bis-choline tetrathiomolybdate

Invented name: Not yet available

Latest Decision number(s): 1) P/0164/2022

Corresponding PIP number(s): 1) EMEA-002232-PIP02-19-M02

Date of initial marketing authorisation granted: Not applicable

Date of authorisation of new indication, pharmaceutical form or route of administration: Not applicable

Please note that development of the medicinal product above in the following
condition(s)/indication(s):

Treatment of Wilson Disease

- ☒ has been discontinued
- ☐ has been suspended/put on long-term hold (with possible re-start at a later time)
- for the following reason(s): (tick all that apply)
- ☐ (possible) lack of efficacy in adults
- ☐ (possible) lack of efficacy in children
- ☐ (possible) unsatisfactory safety profile in adults
- ☐ (possible) unsatisfactory safety profile in children
- ☐ commercial reasons (please specify:)
- ☐ manufacturing / quality problems
- ☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)
- ☐ other reason (please specify:)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

Reference is made to the withdrawal request, on 17 May 2023, of the intent to submit a marketing authorisation application in the EU for ALXN1840 (INN: tiomolibdic acid) as a treatment of Wilson disease. Alexion has decided to terminate the ALXN1840 program in Wilson disease, and as such no marketing authorisation application will be submitted by the end of 2023.

This decision was based off results of Phase 2 mechanistic studies and discussions with regulatory authorities. The Phase 2 mechanism of action studies failed to meet their primary objectives of demonstrating net-negative copper balance in Wilson disease patients during short-term treatment with ALXN1840 and reducing hepatic copper concentration after treatment with ALXN1840. The decision not to progress the ALXN1840 Program in Wilson disease was not related to any safety signals.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point: Signature on file

Date: 30 Aug 2023

Contact for inquiries from interested parties: Alexion Europe S.A.S.

Telephone: +33 1 47 10 36 21

Email: pip.enquiries.eu@alexion.com